# Claritev Corp: financial statements, quarterly

CTEV · NYSE · CIK 1793229 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctev.md) · [Financials](/companies/ctev/financials.md) · [Filings](/companies/ctev/filings.md) · [Insiders](/companies/ctev/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctev/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [243](/filings/0001793229-24-000149.md) | [244 d](/filings/0001793229-26-000017.md) | [235](/filings/0001793229-25-000110.md) | [233](/filings/0001793229-25-000135.md) | [230](/filings/0001793229-25-000170.md) | [232 d](/filings/0001793229-26-000017.md) | [231](/filings/0001793229-26-000046.md) | [242](/filings/0001793229-26-000067.md) | [246](/filings/0001793229-25-000170.md) | [247 d](/filings/0001793229-26-000017.md) | [245](/filings/0001793229-26-000046.md) | [257](/filings/0001793229-26-000067.md) |
| Operating income | $m | [39.5](/filings/0001793229-24-000149.md) | [40.8 d](/filings/0001793229-26-000017.md) | [(486)](/filings/0001793229-25-000110.md) | [(524)](/filings/0001793229-25-000135.md) | [(338)](/filings/0001793229-25-000170.md) | [(41.4) d](/filings/0001793229-26-000017.md) | [9.7](/filings/0001793229-26-000046.md) | [16.6](/filings/0001793229-26-000067.md) | [10.1](/filings/0001793229-25-000170.md) | [(7.6) d](/filings/0001793229-26-000017.md) | [6.6](/filings/0001793229-26-000046.md) | [23.4](/filings/0001793229-26-000067.md) |
| Interest expense | $m | [84.3](/filings/0001793229-23-000122.md) | [83.0 d](/filings/0001793229-24-000012.md) | [82.2](/filings/0001793229-24-000079.md) | [81.1](/filings/0001793229-25-000135.md) | [81.8](/filings/0001793229-25-000170.md) | [81.3 d](/filings/0001793229-26-000017.md) | [91.6](/filings/0001793229-26-000046.md) | [99.7](/filings/0001793229-26-000067.md) | [101](/filings/0001793229-25-000170.md) | [99.4 d](/filings/0001793229-26-000017.md) | [99.5](/filings/0001793229-26-000046.md) | [100](/filings/0001793229-26-000067.md) |
| Income tax | $m | [(6.9)](/filings/0001793229-24-000149.md) | [(0.4) d](/filings/0001793229-26-000017.md) | [(22.0)](/filings/0001793229-25-000110.md) | [(27.5)](/filings/0001793229-25-000135.md) | [(27.2)](/filings/0001793229-25-000170.md) | [(48.2) d](/filings/0001793229-26-000017.md) | [(18.5)](/filings/0001793229-26-000046.md) | [(20.3)](/filings/0001793229-26-000067.md) | [(23.6)](/filings/0001793229-25-000170.md) | [(26.3) d](/filings/0001793229-26-000017.md) | [(19.2)](/filings/0001793229-26-000046.md) | [(17.4)](/filings/0001793229-26-000067.md) |
| Net income | $m | [(24.1)](/filings/0001793229-24-000149.md) | [(31.4) d](/filings/0001793229-26-000017.md) | [(540)](/filings/0001793229-25-000110.md) | [(577)](/filings/0001793229-25-000135.md) | [(391)](/filings/0001793229-25-000170.md) | [(138) d](/filings/0001793229-26-000017.md) | [(71.3)](/filings/0001793229-26-000046.md) | [(62.6)](/filings/0001793229-26-000067.md) | [(69.8)](/filings/0001793229-25-000170.md) | [(80.6) d](/filings/0001793229-26-000017.md) | [(73.6)](/filings/0001793229-26-000046.md) | [(59.2)](/filings/0001793229-26-000067.md) |
| Diluted EPS | $ per share | [(1.49)](/filings/0001793229-24-000149.md) | not reported | [(33.40)](/filings/0001793229-25-000110.md) | [(35.78)](/filings/0001793229-25-000135.md) | [(24.25)](/filings/0001793229-25-000170.md) | not reported | [(4.38)](/filings/0001793229-26-000046.md) | [(3.81)](/filings/0001793229-26-000067.md) | [(4.23)](/filings/0001793229-25-000170.md) | not reported | [(4.41)](/filings/0001793229-26-000046.md) | [(3.49)](/filings/0001793229-26-000067.md) |
| Basic EPS | $ per share | [(1.49)](/filings/0001793229-24-000149.md) | not reported | [(33.40)](/filings/0001793229-25-000110.md) | [(35.78)](/filings/0001793229-25-000135.md) | [(24.25)](/filings/0001793229-25-000170.md) | not reported | [(4.38)](/filings/0001793229-26-000046.md) | [(3.81)](/filings/0001793229-26-000067.md) | [(4.23)](/filings/0001793229-25-000170.md) | not reported | [(4.41)](/filings/0001793229-26-000046.md) | [(3.49)](/filings/0001793229-26-000067.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [101](/filings/0001793229-24-000149.md) | [71.5](/filings/0001793229-26-000017.md) | [58.7](/filings/0001793229-25-000110.md) | [48.8](/filings/0001793229-25-000135.md) | [86.6](/filings/0001793229-25-000170.md) | [16.8](/filings/0001793229-26-000017.md) | [23.1](/filings/0001793229-26-000046.md) | [56.4](/filings/0001793229-26-000067.md) | [39.2](/filings/0001793229-25-000170.md) | [16.8](/filings/0001793229-26-000067.md) | [21.3](/filings/0001793229-26-000046.md) | [14.4](/filings/0001793229-26-000067.md) |
| Current assets | $m | [212](/filings/0001793229-23-000122.md) | [194](/filings/0001793229-25-000022.md) | [190](/filings/0001793229-24-000079.md) | [192](/filings/0001793229-24-000106.md) | [212](/filings/0001793229-24-000149.md) | [176](/filings/0001793229-26-000017.md) | [185](/filings/0001793229-25-000110.md) | [247](/filings/0001793229-25-000135.md) | [257](/filings/0001793229-25-000170.md) | [224](/filings/0001793229-26-000067.md) | [242](/filings/0001793229-26-000046.md) | [236](/filings/0001793229-26-000067.md) |
| Total assets | $m | [7,058](/filings/0001793229-23-000122.md) | [6,965](/filings/0001793229-25-000022.md) | [6,367](/filings/0001793229-24-000079.md) | [5,742](/filings/0001793229-24-000106.md) | [5,319](/filings/0001793229-24-000149.md) | [5,151](/filings/0001793229-26-000017.md) | [5,085](/filings/0001793229-25-000110.md) | [5,072](/filings/0001793229-25-000135.md) | [4,990](/filings/0001793229-25-000170.md) | [4,888](/filings/0001793229-26-000067.md) | [4,839](/filings/0001793229-26-000046.md) | [4,764](/filings/0001793229-26-000067.md) |
| Current liabilities | $m | [172](/filings/0001793229-23-000122.md) | [167](/filings/0001793229-25-000022.md) | [194](/filings/0001793229-24-000079.md) | [181](/filings/0001793229-24-000106.md) | [201](/filings/0001793229-24-000149.md) | [214](/filings/0001793229-26-000017.md) | [180](/filings/0001793229-25-000110.md) | [253](/filings/0001793229-25-000135.md) | [213](/filings/0001793229-25-000170.md) | [261](/filings/0001793229-26-000067.md) | [190](/filings/0001793229-26-000046.md) | [238](/filings/0001793229-26-000067.md) |
| Total liabilities | $m | [5,308](/filings/0001793229-23-000122.md) | [5,256](/filings/0001793229-25-000022.md) | [5,196](/filings/0001793229-24-000079.md) | [5,139](/filings/0001793229-24-000106.md) | [5,112](/filings/0001793229-24-000149.md) | [5,067](/filings/0001793229-26-000017.md) | [5,070](/filings/0001793229-25-000110.md) | [5,112](/filings/0001793229-25-000135.md) | [5,092](/filings/0001793229-25-000170.md) | [5,056](/filings/0001793229-26-000067.md) | [5,074](/filings/0001793229-26-000046.md) | [5,052](/filings/0001793229-26-000067.md) |
| Long-term debt | $m | not reported | [4,600](/filings/0001793229-24-000012.md) | not reported | not reported | not reported | [4,566](/filings/0001793229-25-000022.md) | [4,576](/filings/0001793229-25-000110.md) | [4,588](/filings/0001793229-25-000135.md) | [4,600](/filings/0001793229-25-000170.md) | [4,612](/filings/0001793229-26-000017.md) | [4,625](/filings/0001793229-26-000046.md) | [4,637](/filings/0001793229-26-000067.md) |
| Current portion of debt | $m | [13.3](/filings/0001793229-23-000122.md) | [13.3](/filings/0001793229-25-000022.md) | [13.3](/filings/0001793229-24-000079.md) | [13.3](/filings/0001793229-24-000106.md) | [13.3](/filings/0001793229-24-000149.md) | [13.3](/filings/0001793229-26-000017.md) | [14.7](/filings/0001793229-25-000110.md) | [14.7](/filings/0001793229-25-000135.md) | [14.7](/filings/0001793229-25-000170.md) | [14.7](/filings/0001793229-26-000067.md) | [14.7](/filings/0001793229-26-000046.md) | [14.7](/filings/0001793229-26-000067.md) |
| Shareholders' equity | $m | [1,750](/filings/0001793229-24-000149.md) | [1,709](/filings/0001793229-25-000170.md) | [1,170](/filings/0001793229-25-000135.md) | [603](/filings/0001793229-25-000170.md) | [208](/filings/0001793229-25-000170.md) | [84.0](/filings/0001793229-26-000017.md) | [14.8](/filings/0001793229-25-000135.md) | [(39.9)](/filings/0001793229-25-000170.md) | [(102)](/filings/0001793229-25-000170.md) | [(174)](/filings/0001793229-26-000067.md) | [(241)](/filings/0001793229-26-000046.md) | [(295)](/filings/0001793229-26-000067.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [72.1 d](/filings/0001793229-24-000149.md) | [27.7 d](/filings/0001793229-26-000017.md) | [49.7](/filings/0001793229-25-000110.md) | [18.5 d](/filings/0001793229-25-000135.md) | [72.8 d](/filings/0001793229-25-000170.md) | [(33.4) d](/filings/0001793229-26-000017.md) | [(30.1)](/filings/0001793229-26-000046.md) | [61.2 d](/filings/0001793229-26-000067.md) | [19.9 d](/filings/0001793229-25-000170.md) | [66.3 d](/filings/0001793229-26-000017.md) | [(45.8)](/filings/0001793229-26-000046.md) | [92.7 d](/filings/0001793229-26-000067.md) |
| Capital expenditure | $m | [22.4 d](/filings/0001793229-24-000149.md) | [31.3 d](/filings/0001793229-26-000017.md) | [30.5](/filings/0001793229-25-000110.md) | [25.4 d](/filings/0001793229-25-000135.md) | [31.7 d](/filings/0001793229-25-000170.md) | [30.4 d](/filings/0001793229-26-000017.md) | [38.9](/filings/0001793229-26-000046.md) | [24.6 d](/filings/0001793229-26-000067.md) | [36.2 d](/filings/0001793229-25-000170.md) | [29.9 d](/filings/0001793229-26-000017.md) | [46.8](/filings/0001793229-26-000046.md) | [38.1 d](/filings/0001793229-26-000067.md) |
| Share repurchases | $m | [0.0 d](/filings/0001793229-24-000149.md) | [2.1 d](/filings/0001793229-26-000017.md) | [10.4](/filings/0001793229-25-000110.md) | [0.0](/filings/0001793229-24-000106.md) | [0.0](/filings/0001793229-24-000149.md) | [0.0 d](/filings/0001793229-26-000017.md) | [0.0](/filings/0001793229-25-000110.md) | [0.0 d](/filings/0001793229-26-000067.md) | [0.0 d](/filings/0001793229-25-000170.md) | [0.0 d](/filings/0001793229-26-000017.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [640](/filings/0001793229-23-000122.md) | [641](/filings/0001793229-24-000079.md) | [643](/filings/0001793229-24-000106.md) | [16.2](/filings/0001793229-24-000149.md) | [16.2](/filings/0001793229-25-000110.md) | [16.1](/filings/0001793229-25-000135.md) | [16.1](/filings/0001793229-25-000170.md) | [16.3](/filings/0001793229-26-000046.md) | [16.5](/filings/0001793229-26-000067.md) | [16.5](/filings/0001793229-25-000170.md) | [16.7](/filings/0001793229-26-000046.md) | [17.0](/filings/0001793229-26-000067.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,947,463 at 2026-08-03, from the cover of the [10-Q filed 2026-08-07](/filings/0001793229-26-000067.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.